Anthera Provides Business Update And Reports 2016 Second Quarter Financial Results
HAYWARD, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today provided a business update and reported financial results for the second quarter ended June 30, 2016.
Recent Developments and Business Highlights:
Sollpura™ (liprotamase) – Exocrine Pancreatic Insufficiency (“EPI”)
* Phase 3 SOLUTION Clinical Study Enrollment Target of 126 Patients Met We met the enrollment target in our Phase 3 SOLUTION clinical study evaluating the efficacy and safety of the capsule formulation of Sollpura™ to treat exocrine pancreatic insufficiency in patients with cystic fibrosis in early August. We expect to report topline efficacy data in the fourth quarter of 2016. For more information on the SOLUTION clinical study, please visit http://www.anthera.com/clinical-studies/solution study/.
Recent Developments and Business Highlights:
Sollpura™ (liprotamase) – Exocrine Pancreatic Insufficiency (“EPI”)
* Phase 3 SOLUTION Clinical Study Enrollment Target of 126 Patients Met We met the enrollment target in our Phase 3 SOLUTION clinical study evaluating the efficacy and safety of the capsule formulation of Sollpura™ to treat exocrine pancreatic insufficiency in patients with cystic fibrosis in early August. We expect to report topline efficacy data in the fourth quarter of 2016. For more information on the SOLUTION clinical study, please visit http://www.anthera.com/clinical-studies/solution study/.